Christophe Passot
François Rabelais University
22 Papers
66 Citations
Christophe Passot is an academic researcher from François Rabelais University. The author has contributed to research in topics: Infliximab & Medicine. The author has an hindex of 11, co-authored 20 publications.
Chat about Author
Papers
Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Claire Bonneau,Gilles Paintaud,Olivier Tredan,Coraline Dubot,Céline Desvignes,Véronique Diéras,S. Taillibert,P. Tresca,Isabelle Turbiez,Jacques Li,Christophe Passot,Fawzia Mefti,Emmanuelle Mouret-Fourme,Emilie Le Rhun,Maya Gutierrez +14 more
TL;DR: A phase I dose-escalation study of intrathecal administration of trastuzumab in HER2-BC patients with MC to determine the maximum tolerated dose (MTD), which was based on both the achievement of a trastizumab intra-cerebrospinal fluid concentration close to a conventional therapeutic plasma concentration and/or dose-limiting toxicity (DLT).
87
IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
David Ternant,Christophe Arnoult,Martine Pugnière,Christine Dhommée,Daniel Drocourt,Eric Perouzel,Christophe Passot,Nadine Baroukh,Denis Mulleman,Gérard Tiraby,Hervé Watier,Gilles Paintaud,Valérie Gouilleux-Gruart +12 more
TL;DR: G1m17,1 mAbs, such as infliximab and rituximab, were shown to bind more efficiently to FcRn and to be transcytosed better than the G1m3,-1 mAb cetuximabs, which explains why inflixIMab is a better competitor for endogenous IgG1 in G1M3,1 allotype–bearing patients.
68
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies
Christophe Passot,Nicolas Azzopardi,Sylvaine Renault,Nadine Baroukh,Christophe Arnoult,Marc Ohresser,Michèle Boisdron-Celle,Erick Gamelin,Hervé Watier,Gilles Paintaud,Valérie Gouilleux-Gruart +10 more
TL;DR: The relationship between FCGRT polymorphisms (VNTR and CNV) and PK parameters of patients treated with cetuximab was studied and no affects of VNTR genotype on elimination clearance were observed.
64
A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers.
Frédéric Dumont,Christophe Passot,Jean-Luc Raoul,Vahan Kepenekian,Bénédicte Lelièvre,Michelle Boisdron-Celle,Sandrine Hiret,Hélène Senellart,F Pein,Audrey Blanc-Lapierre,Judith Raimbourg,Emilie Thibaudeau,Olivier Glehen,Big-Renape Networks +13 more
TL;DR: The maximum tolerated dose (MTD) of oxaliplatin during PIPAC is 90 mg/m2 and PK data demonstrate a high tumour concentration and a significant systemic absorption.
45
Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.
Bertrand Lioger,Soujanya Ratna Edupuganti,Denis Mulleman,Christophe Passot,Céline Desvignes,Theodora Bejan-Angoulvant,Gilles Thibault,Valérie Gouilleux-Gruart,Julien Mélet,Gilles Paintaud,David Ternant +10 more
TL;DR: The association between CD19+ count and k10 may be explained by target-mediated drug disposition, while the association between IgG serum concentration and k 10 may be explaining by a saturation of the neonatal Fc receptor at high IgG concentrations, resulting in decreased recycling of rituximab.
27